angioblast


Also found in: Encyclopedia, Wikipedia.

angioblast

 [an´je-o-blast″]
1. the earliest formative tissue from which blood cells and blood vessels arise.
2. an individual vessel-forming cell. adj., adj angioblast´ic.

an·gi·o·blast

(an'jē-ō-blast),
1. A cell taking part in blood vessel formation. Synonym(s): vasoformative cell
2. Primordial mesenchymal tissue from which embryonic blood cells and vascular endothelium are differentiated. Synonym(s): angioderm
[angio- + G. blastos, germ]

angioblast

/an·gio·blast/ (an´je-o-blast″)
1. the embryonic mesenchymal tissue from which blood cells and blood vessels arise.
2. an individual vessel-forming cell.angioblas´tic

angioblast

(ăn′jē-ə-blăst′)
n.
1. A cell taking part in blood vessel formation.
2. The primordial mesenchymal tissue from which embryonic blood cells and vascular endothelium are differentiated.

angioblast

[an′jēō·blast′]
Etymology: Gk, angeion, vessel + blastos, germ
1 the mesenchymal tissue of the embryo from which the blood cells and blood vessels differentiate.
2 an individual vessel-forming cell.

angioblast

A primitive mesenchymal tissue that develops into bone marrow and blood vessels. Angioblasts appear at the primitive streak stage, in the body stalk, and in the yolk sac within blood islands.

an·gi·o·blast

(an'jē-ō-blast)
1. A cell taking part in blood vessel formation.
Synonym(s): vasoformative cell.
2. Primordial mesenchymal tissue from which embryonic blood cells and vascular endothelium are differentiated.
[angio- + G. blastos, germ]

angioblast

1. the earliest formative tissue from which blood cells and blood vessels arise.
2. an individual vessel-forming cell.
References in periodicals archive ?
3 World Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024 Companies Listed Aastrom Biosciences Adiposet Ltd (merged into Regenerys) Advanced BioHealing (acquired by Shire) Advanced Cell Technology (ACT) Advanced Tissue Sciences (ATS) Advantagene Allosource AlphaTec Spine Altrika (acquired by Regenerys) Amedica Amgen Amorcyte (acquired by NeoStem) Amorepacific Corporation Amsterdam Molecular Therapeutics (predecessor of UniQure) AnGes MG Angioblast Systems (acquired by Mesoblast) Anika Therapeutics AnorMED (acquired by Genzyme) Anterogen (subsidiary of Bukwang Pharm Co Ltd) Arcarios B.
Melbourne, Australia, Nov 8, 2010 - (ABN Newswire) - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (USOTC:MBLTY), today announced that its United States associate company, Angioblast Systems, has been awarded $1.
MELBOURNE, Australia, November 8, 2010 /PRNewswire/ -- Regenerative medicine company, Mesoblast Limited (ASX: MSB; USADR: MBLTY), today announced that its United States associate company, Angioblast Systems, has been awarded US$1.
Melbourne, Australia, Sep 22, 2010 - (ABN Newswire) - Shareholders of Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today overwhelmingly approved the acquisition of its United States associate company, Angioblast Systems Inc.
At the same time, our associate company in the United States, Angioblast Systems Inc.
Phase 2 trial of Revascor (TM) rdiac repair stem cell product, being developed by Mesoblast's United States associated company Angioblast Systems Inc.
On Wednesday 22 September 2010, Mesoblast Limited (ASX:MSB) (PINK:MBLTY) will hold an Extraordinary General Meeting of shareholders to consider a proposed acquisition of its United States-based associate company, Angioblast Systems Inc.
FIRST HEART FAILURE PATIENTS SUCCESSFULLY IMPLANTED WITH ANGIOBLAST SYSTEMS' "OFF-THE-SHELF" ADULT STEM CELLS
Chief Executive, Professor Silviu Itescu, updated investors on Mesoblast's acquisition of its United States associate company, Angioblast Systems, its near term growth strategies and plans for early product revenues.
Melbourne, Australia, April 6, 2010 - (ABN Newswire) - Australian regenerative medicine company and biologic innovator, Mesoblast Limited (ASX:MSB) (OTC:MBLTY), today provided an assessment on how the recently enacted United States Patient Protection and Affordable Care Act (HB 3590) is expected to have a positive impact on the commercial prospects for both Mesoblast and its United States-associated company, Angioblast Systems Inc.
The Company has also acquired a substantial interest in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle.